Newsletter · · Ashutosh Agarwal

Pharma Buyouts Now Close in 46 Days as the FTC Steps Aside - Biotech M&A Weekly - Week of July 17, 2026

Biotech M&A podcast intelligence for the week of July 17, 2026. Billion-dollar biopharma takeouts are now closing in an average of 46 days versus 112, and the week's podcasts named the takeover targets in play, from Revolution Medicines to Vera Therapeutics.

Biotech M&A Weekly

Week of July 17, 2026: Pharma Buyouts Now Close in 46 Days as the FTC Steps Aside

July 17, 2026

For two years the biotech M&A story has been about why, the patent cliff is coming, biotech is cheap, pharma has cash, so a takeover wave makes sense. This week the story shifted to how fast. A deal-tracker at Scrip pulled the numbers and found something genuinely new: the big biotech buyouts of 2026 are closing in less than half the time they used to. The regulators have stepped out of the way, and pharma is sprinting through the door before anything changes.

TL;DR

  • Deals are closing at roughly double the old speed. Billion-dollar-plus biopharma takeouts are getting from announcement to done in an average of 46 days this year, versus 112 days across 2023–2025. GSK's $10.6 billion purchase of Nuvalent closed in 36 days. The reason, straight from a former healthcare banker: a friendlier Federal Trade Commission and a wave of simple, all-cash "buy one drug" deals.
  • The cliff got re-sized, bigger. Big pharma is now said to be staring down "somewhere in the neighborhood of $230 billion" of revenue rolling off patent by 2030, too much to replace with in-house research alone. That is up from the ~$180 billion figure a different guest used last week. Either way: the buyers have no choice but to keep buying.
  • The XBI is still near the top of the world, literally. One technical-analysis show ranked biotech the third-best-performing asset group on the planet, behind only Japanese stocks and the S&P 500. Even the biotech insiders admit the M&A frenzy is getting "a little frothy."

What's new

The headline number: 46 days versus 112. The most useful data of the week came from the July edition of Citeline's Scrip Deals Podcast, where Scrip's deals editor Joe Haas walked through his own count with guest Dr. Bruce Leuchter, a biotech CEO (Nirvati Biosciences and Grin Therapeutics) who used to be an analyst at Goldman Sachs and a healthcare banker at Credit Suisse, so he has sat on every side of these tables. Haas's tally: 36 deals worth $1 billion or more so far this year, 12 of them already closed, and five deals north of $10 billion.

Here's the part that jumps out. For the $1 billion-plus deals done since the start of 2026, the average gap between announcing a deal and completing it is 46 days. From 2023 through 2025, that same average was 112 days, about 3.7 months. As Haas put it, "deals this year are closing in less than half of the time on average," and nine of the twelve closed in a tight 28-to-48-day window, including GSK's $10.6 billion takeout of Nuvalent, which "closed on July 15th, 36 days after it was announced."

Why the speed-up? Leuchter gave two reasons, and neither is a coincidence. The first is the regulator. "That administration is clearly assuming a different posture at the FTC level than we experienced in the prior administration. And that is a welcome change for the M&A markets and has likely facilitated less friction and more velocity." (The FTC is the US antitrust cop; in plain terms, it now says "yes" faster and asks fewer follow-up questions on routine deals.) The second reason is the kind of deal being done, which brings us to the next point.

Pharma is buying single drugs, not sprawling science projects. Leuchter's framing is the cleanest way to understand 2026: the buyers are taking "rifle shots at assets." They know exactly which hole in their portfolio they're filling, they target a late-stage or already-approved drug, and they pay cash. That is fast and clean. Compare that to a "platform" deal, buying a company with dozens of early experiments and unproven technology, which takes far longer to evaluate and integrate. Roughly 80% of this year's deals, he estimates, are in that simple "asset-centric zip code." Even a $10 billion deal can be simple: he describes AbbVie's roughly $10 billion agreement to buy Apogee as "a bolt-on transaction to the immunoscience franchise at AbbVie," a big check for one focused purpose, not a merger of empires.

He also flagged the deals that haven't closed yet, and why. Four of the year's $10 billion-plus deals are still open: private-equity firm CVC buying Italy's Recordati, Sun Pharma buying Organon, AbbVie/Apogee, and Vertex/Crinetics. The two involving non-US buyers and private equity are the complicated ones; the two straightforward drug deals should close on the fast timetable. For comparison, Gilead's $7.8 billion purchase of Arcellx took 64 days, and Otsuka's buy of Transcend (about $700 million up front, over $1.2 billion in total) took 77, the slowest of the year, which Leuchter chalks up to it being a cross-border deal with a Japanese acquirer.

"We do need M&A in this industry and it's what helps keep the trains on the track." Dr. Bruce Leuchter, on why the deal wave is healthy, not a warning sign

One more nuance worth holding onto: the competition for good assets isn't only other drug companies. Leuchter and Haas described a roughly $7 billion deal where the buyer's rival wasn't another pharma, it was a financing offer the target had lined up that valued it richly. The buyer had to raise its bid to win. The word Leuchter kept returning to was "scarcity value": there aren't that many genuinely good, de-risked drugs, so when one appears, everybody, acquirers and investors alike, bids for it.

The cliff, re-measured. The single number that anchors this whole newsletter also got refreshed this week. Leuchter put big pharma's looming patent losses at "somewhere in the neighborhood of $230 billion by 2030... Really, really hard to make up for that kind of LOE loss by internal innovation only." ("LOE" is loss of exclusivity, the moment cheap copies can legally compete and a blockbuster's sales fall off a cliff.) Note the drift: last week's issue quoted a veteran investor putting the 2030 hole at ~$180 billion. Different people, different math, same unavoidable conclusion, the number is enormous and internal labs can't fill it, so the checkbook comes out.

The quarter's scoreboard confirms it. Backing up the anecdotes with tallies, the deals editor noted that in the second quarter alone, M&A volume rose 14% from a year earlier, valuations jumped 41%, and there were 47 deals with total potential value, including all the milestone payments and earn-outs, of more than $77 billion. Over on BioCentury This Week, BioCentury's Stephen Hansen added a striking figure: there were 39 billion-dollar-plus deals in all of last year, and the industry already did 33 in the first half of this year alone.

Where the takeout cash actually goes, and why the market keeps grinding higher. This was the most useful insight from the BioCentury crew. Hansen's team looked at the 15 public biotechs bought for more than $1 billion in the first half and dug into who owned them. The answer: "about $22.8 billion... being returned to specialist investors," the biotech-focused funds that held those stocks. That money doesn't leave the sector; it gets reinvested into the next batch of names. His practical tip for readers: "if you're looking at a ticker and you see like a 3% or a 5% jump on any given day where there isn't news, that very well could be... specialists coming in and buying into a new name" with cash from a deal that just paid out. In other words, every takeout quietly funds the next rally.

Eli Lilly keeps spending, this time on psychedelics. On STAT's The Readout Loud, the hosts reported Lilly's newest deal: buying Atai/Beckley for "$2.8 billion in cash up front with the potential for another $1 billion contingent on milestones." That second billion is a CVR, a contingent value right, essentially an IOU that only pays if the drug hits agreed targets, a way for buyer and seller to split the risk of an unproven medicine. The asset is a fast-acting psychedelic (a form of 5-MeO-DMT) for depression that doesn't respond to normal treatment. Reporter Elaine Chen's read: Lilly "has so much money to spend, it's able to go out and bet on riskier bets," this is a company with no cliff of its own throwing weight around in areas others won't touch.

The debate

Like last week, the podcasts leaned heavily bullish, but the balance shifted in an important way. Last week, nobody even mentioned the FTC. This week, the FTC is the whole bull case. That is a real change, and it deserves both sides.

The bull case is now explicit and, unusually, comes from someone who does deals for a living. Leuchter's argument is that the two things that used to kill biopharma M&A have both gone away at once. Regulatory fear has faded, "regulatory overhang... has definitively gone away or has been substantially mitigated. So open season, I suppose, is the right terminology." And the valuation standoff has resolved: two years ago biotech shares were so beaten down that boards refused to sell for what buyers offered, but this year's recovery (the XBI is up roughly 25%) has created "a decent meeting in the middle" where sellers feel fairly valued and buyers aren't priced out. Add the $230 billion cliff forcing pharma's hand, and you get a self-reinforcing wave.

The bear case was thinner, and it came in two flavors. The first is Leuchter's own caveat, the one exception that could gum up the machine: drug pricing. He warned that pricing "remain[s] a flashpoint for the administration and for Congress," pointing to tariffs and "most favored nation" pricing (the idea of forcing US drug prices down to what other rich countries pay). If that fight turns ugly, it "could have impact... on time of announcement to close." So the risk to the deal wave isn't the antitrust cop anymore, it is the pricing politician.

The second flavor is bigger and stranger: what if the AI stock bubble pops? BioCentury's Hansen relayed a worry he kept hearing from investors. He noted that the seven companies making the biggest AI bets, Nvidia, OpenAI, Anthropic, Alphabet, Meta, Microsoft and SpaceX, were worth over $17 trillion combined at quarter-end, equal to about 53% of the entire US economy. If that trade unwinds, one camp fears it "drag[s] everything down," biotech included, as investors face losses and pull money from every kind of fund. The other camp thinks the opposite, that money fleeing a popped AI bubble would "go looking for alpha in other parts of the market," and biotech is an obvious place to look. One buysider likened it to "feeling the rumblings of an earthquake." Nobody knows which way it breaks, but it is the macro wildcard now sitting over the sector.

What you still won't find is anyone arguing the deals themselves are dumb, that pharma is overpaying, or that these drugs won't work. The frothy-valuation worry exists (the Biotech Hangout crew called the M&A speculation "a little bit frothy... always a little bit of a dangerous place to be"), but even they added that "industry fundamentals [are] better than they've ever been."

The names in play

This week's specific names came from a biotech specialist who goes by "Seedy" on the Value Hive Podcast, a single, opinionated individual investor, so treat these as one sharp person's convictions, not house calls. His overarching point is a good one for non-specialists: small biotechs come with a built-in exit. Most never intend to sell their own drugs worldwide, so the natural endgame is getting bought, usually at "2.2 to 3 times sales." And there's a clock: good drugs tend to get acquired "between three to 12 months of [FDA] approval," and if a company passes 12 months un-bought, it's probably going to go it alone.

  • Revolution Medicines (RVMD), his marquee example of scarcity value. It is worth about $40 billion "but they haven't sold a single dime" of product yet. He claims that "Merck and AbbVie were trying to buy it... both of them failed to acquire it because they just got priced out," and management "stood their ground." (This echoes last week's chatter about RevMed walking away from Merck, the story that a top asset is now too expensive even for big pharma.) Treat the "priced out" detail as an investor's assertion, not confirmed fact.
  • Erasca (ERAS), his "if you can't afford RevMed, buy the copy" idea. It has a similar cancer drug (targeting RAS, a notorious cancer pathway); RevMed is even suing it for patent infringement. He argues the legal risk is "overblown" because the molecule originated with a Chinese company, and that a big buyer shut out of RevMed "could get... a similar molecule for one fourth of the price." He sees "50% to 100% left in the valuation."
  • Vera Therapeutics (VERA), a kidney-disease (IgAN) drug that just won a clean FDA approval, competing with an Otsuka product, with over $1 billion in peak-sales potential. His call: "Vera is going to get acquired... a bolt-on deal," pointing to Vertex's earlier takeout of Alpine in the same space as the template.

On the buyer side, the standout remains Vertex (VRTX). The Biotech Hangout analysts, who cover it, dissected its roughly $10 billion (about $9 billion net of cash) purchase of Crinetics, a move into rare hormonal diseases, at "almost a hundred percent premium." Vertex says the acquired drugs could deliver ~$5 billion in combined peak sales; the only real debate the hosts heard was "did they overpay?", and their answer was essentially that for a $130 billion company diversifying beyond cystic fibrosis, a little overpayment doesn't much matter.

Read-throughs

  • Biosimilars, the plumbing still doesn't work, and here's why in one story. A re-released Working Healthcare episode featured Chuck Melendi, a recently retired J&J policy executive, an insider, though note this aired as a re-run, so it is context rather than fresh news. His most concrete point: doctors' offices often can't afford to switch patients to a cheaper biosimilar because "we get reimbursed by Medicare... or the insurance company less than what we can buy the drug for." He cited biosimilars of J&J's old blockbuster Remicade (Amgen's Avsola, Pfizer's Inflectra) and noted UnitedHealthcare mandating an Actemra biosimilar as its preferred option from June 1. He also confirmed J&J's strategic choice to stay out of biosimilars entirely, "we're going to focus on bringing innovative medicines," and, memorably, that "you could be AbbVie and protect Humira for way more than 20 years" with a good legal team. The read-through: if you're underwriting a biosimilar maker's growth, the obstacle isn't the science, it's the payment system, and it still isn't fixed.
  • The GLP-1 patent cliff has arrived overseas, a live preview of what LOE looks like. Morgan Stanley's Thoughts on the Market offered a real-time case study, with analysts Terence Flynn and Thibault Boutherin. Semaglutide (the molecule in Ozempic and Wegovy) lost patent protection in India in March 2026, and 13 companies promptly launched 26 generic versions, which grabbed 80% of volume by April, while total volume ran six times higher than February. Their forecast: India's GLP-1 market grows from $125 million to over $1 billion by 2030 despite lower prices, because cheap drugs reach far more patients. The US cliff for semaglutide isn't until 2032 (Europe 2031), but the overseas experiment shows the shape of it. Their hedge: the newer drug tirzepatide (Lilly's Mounjaro/Zepbound), which works on two pathways instead of one, looks "less at risk" and should keep growing at a premium.
  • Bankers and CROs, still no distinct call. A deal-a-week pace obviously helps the advisory banks, and one show made the case that AI is quietly reshaping how deals even get sourced, an AI For Pharma Growth guest argued that work which "takes three to four weeks" and a team of analysts is being compressed by software, so business-development teams may soon need "one senior level person" instead of a bench of juniors. But no one voiced a specific, investable thesis on a named bank or contract research organization (the outsourced labs that run drug trials) this week.

What changed

The biggest shift from last week is the FTC. Seven days ago the takeover wave was being celebrated with a notable silence, nobody mentioned antitrust at all, and this newsletter flagged that absence twice. This week a former banker made the friendly FTC the centerpiece of the bull thesis and, crucially, attached numbers to it: deals closing in 46 days instead of 112, second follow-up reviews largely gone, "open season." The story moved from "look how many deals are happening" to "look how frictionlessly they're happening, and here's exactly why."

Two smaller shifts. First, the cliff got bigger on paper, this week's $230 billion versus last week's ~$180 billion, a reminder that these are estimates, but pointing the same direction. Second, the risk narrative rotated. Last week the overhang to watch was drug pricing (the IRA and most-favored-nation rules). That is still on the list, Leuchter named it as the one thing that could slow the machine, but a new, larger wildcard arrived: the fear that a bursting AI-stock bubble could either flood biotech with fleeing capital or drag it down with everything else. For now, the deals keep printing and closing faster than ever. The question the tape is quietly asking is what happens to all this momentum if the biggest trade in the market finally cracks.